Aquatic Capital Management LLC Sells 5,953 Shares of Merus (NASDAQ:MRUS)

Aquatic Capital Management LLC lessened its holdings in Merus (NASDAQ:MRUS - Free Report) by 24.6% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,247 shares of the biotechnology company's stock after selling 5,953 shares during the period. Aquatic Capital Management LLC's holdings in Merus were worth $767,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. FMR LLC boosted its position in Merus by 0.4% in the fourth quarter. FMR LLC now owns 6,899,521 shares of the biotechnology company's stock worth $290,125,000 after purchasing an additional 25,595 shares during the last quarter. Wellington Management Group LLP grew its position in Merus by 21.1% during the fourth quarter. Wellington Management Group LLP now owns 3,497,653 shares of the biotechnology company's stock valued at $147,076,000 after buying an additional 610,139 shares during the period. Franklin Resources Inc. increased its holdings in Merus by 7.1% during the third quarter. Franklin Resources Inc. now owns 2,256,504 shares of the biotechnology company's stock worth $117,722,000 after buying an additional 150,341 shares during the last quarter. Avoro Capital Advisors LLC raised its position in Merus by 56.8% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,125,000 shares of the biotechnology company's stock worth $89,356,000 after acquiring an additional 770,000 shares during the period. Finally, Pictet Asset Management Holding SA boosted its stake in Merus by 1.9% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,031,827 shares of the biotechnology company's stock valued at $43,388,000 after acquiring an additional 19,379 shares during the last quarter. Hedge funds and other institutional investors own 96.14% of the company's stock.

Merus Stock Down 6.4 %

NASDAQ:MRUS traded down $2.77 during trading hours on Tuesday, hitting $40.59. 104,989 shares of the company's stock traded hands, compared to its average volume of 708,543. Merus has a 52 week low of $33.19 and a 52 week high of $61.61. The business's fifty day simple moving average is $43.92 and its two-hundred day simple moving average is $44.36. The firm has a market cap of $2.81 billion, a P/E ratio of -10.31 and a beta of 0.94.

Merus (NASDAQ:MRUS - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.48. The firm had revenue of $9.14 million during the quarter, compared to the consensus estimate of $10.57 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. On average, analysts expect that Merus will post -3.85 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $85.00 price target on shares of Merus in a report on Monday, March 3rd. Wells Fargo & Company assumed coverage on Merus in a research note on Friday, February 7th. They set an "overweight" rating and a $91.00 price target for the company. William Blair restated an "outperform" rating on shares of Merus in a research note on Monday, April 28th. Piper Sandler started coverage on shares of Merus in a research report on Thursday, February 13th. They set an "overweight" rating and a $84.00 target price for the company. Finally, Bank of America lowered their price target on shares of Merus from $73.00 to $70.00 and set a "buy" rating on the stock in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Merus currently has an average rating of "Buy" and a consensus price target of $85.31.

Merus Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.